GSK’s Clinical Development Plan For Jemperli In Rectal Cancer Draws US FDA Concerns

Oncologic Drugs Advisory Committee asked to weigh in on adequacy of GSK’s proposal for two single-arm trials to support accelerated approval in a curative setting, as well as the potential novel use of clinical complete response as an approval endpoint.